Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Connect Biopharma Holdings Ltd ADR (NQ: CNTB )

1.450 +0.350 (+31.82%)
Streaming Delayed Price Updated: 3:25 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,175,852
Open 1.270
Bid (Size) 1.430 (3)
Ask (Size) 1.450 (4)
Prev. Close 1.100
Today's Range 1.230 - 1.580
52wk Range 0.5573 - 4.175
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the trading week with a breakdown of the biggest pre-market stock movers for Monday and what's behind that movement! 
Via InvestorPlace
Connect Biopharma's Atopic Dermatitis Candidate Shows Rapid, Sustained Improvement Across All Body Regions
Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced post hoc data analysis from the Phase 2b CBP-201 global trial in moderate-to-severe atopic dermatitis (AD). 
Via Benzinga

Performance

YTD
+68.60%
+68.60%
1 Month
+35.51%
+35.51%
3 Month
+103.59%
+103.59%
6 Month
+3.57%
+3.57%
1 Year
-61.74%
-61.74%

More News

Read More
Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms
From Connect Biopharma Holdings Limited
Via Business Wire
Connect Biopharma Lead Candidate Aces Pivotal Atopic Dermatitis Trial In Chinese Patients
Via Benzinga
Connect Biopharma's Candidate For Skin Disease-Associated Itch Shows Encouraging Safety Profile
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions
From Connect Biopharma Holdings Limited
Via Business Wire
Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting
From Connect Biopharma Holdings Limited
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Connect Biopharma To Present at Upcoming Investor and Scientific Conferences
From Connect Biopharma Holdings Limited
Via Globe NewsWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Week In Review: AIM Vaccine Stages $20 Million IPO On Hong Kong Exchange
Via Talk Markets
Why KalVista Pharmaceuticals Shares Are Trading Lower By 59%; Here Are 89 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
From Connect Biopharma Holdings Limited
Via Globe NewsWire
Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
From Connect Biopharma Holdings Limited
Via Globe NewsWire
Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis
From Connect Biopharma Holdings Limited
Via Globe NewsWire
Earnings Scheduled For September 13, 2022
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Week In Review: Qiming Closes $3.2 Billion For China Healthcare And Technology Investments
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.